EMVISION MEDICAL DEVICES ORD
EMVision Expands Pivotal FDA Trial to Include Acute Ischaemia Detection
EMVision expands FDA De Novo trial to include acute ischaemia detection for its emu device, widening indications as recruitment hits 125 and cash AUD 18.4m.
EMVision Medical Devices Activates New US Site for Pivotal emu Brain Scanner Trial
Premier US stroke research hub UCLA Health will act as the site for a validation trial and continuous innovation study of EMVision Medical Devices’ (ASX: EMV) new emu brain scanner. The trial site will be led by principal investigator Dr May Nour, a dually-trained vascular and interventional neurologist and medical director of California’s first mobile […]
EMVision Medical Devices’ First Responder passes aeromedical testing for stroke and TBI care
EMVision Medical Devices (ASX: EMV) has completed aeromedical retrieval environment testing of its First Responder proof-of-concept (PoC) device to treat rural patients with stroke and traumatic brain injury (TBI). The company used the world-first brain imaging device to collect a series of volunteer scans in remote settings in collaboration with the Royal Flying Doctor Service […]
EMVision Medical Devices’ interim trial data shows promising results in identifying stroke types
Stage 2 interim data from a pre-validation trial by EMVision Medical Devices (ASX: EMV) has confirmed the positive performance of neurodiagnostic artificial intelligence (AI) algorithms in the diagnosis of suspected haemorrhagic or ischaemic strokes. The data showed the algorithms had an “encouraging ability” to identify patterns and features across complex ischaemic patient data sets, including […]